Cystic fibrosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 17: | Line 17: | ||
Class IV: [[Conductance Defect|Conductance Defect]] | Class IV: [[Conductance Defect|Conductance Defect]] | ||
Class V: [[Reduced Protein Synthesis|Reduced Protein Synthesis]] | Class V: [[Reduced Protein Synthesis|Reduced Protein Synthesis]] | ||
| |||
== Approaches to Treatment == | |||
==== Lung Function ==== | |||
[[Physiotherapy and mucolytics|Physiotherapy and mucolytics]] | |||
Oral and Inhaled [[Antibotics|Antibotics]] | |||
[[Anti-Inflammatory|Anti-Inflammatory Drugs]] | |||
[[Transplant|Lung Transplant]] | |||
[[Gene therapy|Gene Therapy]] | |||
[[Pharmacotherapy|Pharmacotherapy]] | |||
[[Alternative Channel Therapy|Alternative Channel Therapy]] | |||
===== Pancreatic Function ===== | |||
[[Pancreatic Enzyme Replacement|Pancreatic Enzyme Replacement]] | |||
Nutrional Regime |
Revision as of 11:38, 8 November 2010
Cystic Fibrosis
Cystic Fibrosis is an autosomal recessive disease located on chromosome 7. Cystic Fibrosis is caused by a mutation to the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) channel. The most common mutation is ΔF508, accounting for 70% of mutations in the Caucasin UK population, in which the triplet code for the amino acid phenylalanine is deleted, disrupting Cl- transport. This mutation belongs to the Class II group of mutations causing Cystic Fibrosis.
Classes of CFTR Mutations
Class I: Premature Stop Codons
Class II: Abnormal Processing
Class III: Altered Regulation
Class IV: Conductance Defect
Class V: Reduced Protein Synthesis
Approaches to Treatment
Lung Function
Oral and Inhaled Antibotics
Pancreatic Function
Nutrional Regime